The novel roles of stromal fibroblasts in metronomic chemotherapy: Focusing on cancer stemness and immunity

Research output: Contribution to journalReview article

Abstract

Metronomic chemotherapy involves the administration of cytotoxic chemotherapy at reduced doses administered at regular and frequent intervals. Low-dose metronomic (LDM) chemotherapy represents an alternative to standard maximum tolerated dose (MTD) chemotherapy as it is less toxic and offers additional beneficial biological effects; such effects include inhibition of tumor neovascularization and reduced recruitment of immune-suppressive cells. In desmoplastic cancers such as breast and pancreatic cancers, carcinoma-associated fibroblasts (CAFs) in the tumor stroma constitute an important cellular target of systemic chemotherapy, and the treatment-modulated CAFs may deleteriously influence treatment efficacy. Herein, we reviewed the novel roles of CAFs in metronomic chemotherapy in desmoplastic cancers. We discuss the differential effects of MTD- and LDM-chemotherapy on the heterotypic interactions among CAFs and cells in the other cancer compartments, emphasizing the roles of cancer stem cells and myeloid-derived suppressor cells. The novel mechanistic roles of CAFs in cancer therapy provide an additional rationale for the clinical development of LDM chemotherapy.
Original languageEnglish
Pages (from-to)123-126
Number of pages4
Journal台灣癌症醫學雜誌
Volume4
Issue number4
DOIs
Publication statusPublished - 2017

Fingerprint

Immunity
Fibroblasts
Drug Therapy
Neoplasms
Carcinoma
Maximum Tolerated Dose
Neoplastic Stem Cells
Poisons
Pancreatic Neoplasms
Breast Neoplasms
Therapeutics

Cite this

The novel roles of stromal fibroblasts in metronomic chemotherapy: Focusing on cancer stemness and immunity. / Liao, Wen-Ying; Chan, Tze-Sian; Tsai, Kelvin K.

In: 台灣癌症醫學雜誌, Vol. 4, No. 4, 2017, p. 123-126.

Research output: Contribution to journalReview article

@article{235e18011cc44812b3245b23138d4856,
title = "The novel roles of stromal fibroblasts in metronomic chemotherapy: Focusing on cancer stemness and immunity",
abstract = "Metronomic chemotherapy involves the administration of cytotoxic chemotherapy at reduced doses administered at regular and frequent intervals. Low-dose metronomic (LDM) chemotherapy represents an alternative to standard maximum tolerated dose (MTD) chemotherapy as it is less toxic and offers additional beneficial biological effects; such effects include inhibition of tumor neovascularization and reduced recruitment of immune-suppressive cells. In desmoplastic cancers such as breast and pancreatic cancers, carcinoma-associated fibroblasts (CAFs) in the tumor stroma constitute an important cellular target of systemic chemotherapy, and the treatment-modulated CAFs may deleteriously influence treatment efficacy. Herein, we reviewed the novel roles of CAFs in metronomic chemotherapy in desmoplastic cancers. We discuss the differential effects of MTD- and LDM-chemotherapy on the heterotypic interactions among CAFs and cells in the other cancer compartments, emphasizing the roles of cancer stem cells and myeloid-derived suppressor cells. The novel mechanistic roles of CAFs in cancer therapy provide an additional rationale for the clinical development of LDM chemotherapy.",
keywords = "Carcinoma-associated fibroblasts, Metronomic chemotherapy, Cancer stemness, Myeloid-derived suppressor cells",
author = "Wen-Ying Liao and Tze-Sian Chan and Tsai, {Kelvin K.}",
year = "2017",
doi = "10.1016/j.jcrpr.2017.08.001",
language = "English",
volume = "4",
pages = "123--126",
journal = "Journal of Cancer Research and Practice",
issn = "2311-3006",
publisher = "中華民國癌症醫學會",
number = "4",

}

TY - JOUR

T1 - The novel roles of stromal fibroblasts in metronomic chemotherapy: Focusing on cancer stemness and immunity

AU - Liao, Wen-Ying

AU - Chan, Tze-Sian

AU - Tsai, Kelvin K.

PY - 2017

Y1 - 2017

N2 - Metronomic chemotherapy involves the administration of cytotoxic chemotherapy at reduced doses administered at regular and frequent intervals. Low-dose metronomic (LDM) chemotherapy represents an alternative to standard maximum tolerated dose (MTD) chemotherapy as it is less toxic and offers additional beneficial biological effects; such effects include inhibition of tumor neovascularization and reduced recruitment of immune-suppressive cells. In desmoplastic cancers such as breast and pancreatic cancers, carcinoma-associated fibroblasts (CAFs) in the tumor stroma constitute an important cellular target of systemic chemotherapy, and the treatment-modulated CAFs may deleteriously influence treatment efficacy. Herein, we reviewed the novel roles of CAFs in metronomic chemotherapy in desmoplastic cancers. We discuss the differential effects of MTD- and LDM-chemotherapy on the heterotypic interactions among CAFs and cells in the other cancer compartments, emphasizing the roles of cancer stem cells and myeloid-derived suppressor cells. The novel mechanistic roles of CAFs in cancer therapy provide an additional rationale for the clinical development of LDM chemotherapy.

AB - Metronomic chemotherapy involves the administration of cytotoxic chemotherapy at reduced doses administered at regular and frequent intervals. Low-dose metronomic (LDM) chemotherapy represents an alternative to standard maximum tolerated dose (MTD) chemotherapy as it is less toxic and offers additional beneficial biological effects; such effects include inhibition of tumor neovascularization and reduced recruitment of immune-suppressive cells. In desmoplastic cancers such as breast and pancreatic cancers, carcinoma-associated fibroblasts (CAFs) in the tumor stroma constitute an important cellular target of systemic chemotherapy, and the treatment-modulated CAFs may deleteriously influence treatment efficacy. Herein, we reviewed the novel roles of CAFs in metronomic chemotherapy in desmoplastic cancers. We discuss the differential effects of MTD- and LDM-chemotherapy on the heterotypic interactions among CAFs and cells in the other cancer compartments, emphasizing the roles of cancer stem cells and myeloid-derived suppressor cells. The novel mechanistic roles of CAFs in cancer therapy provide an additional rationale for the clinical development of LDM chemotherapy.

KW - Carcinoma-associated fibroblasts

KW - Metronomic chemotherapy

KW - Cancer stemness

KW - Myeloid-derived suppressor cells

U2 - 10.1016/j.jcrpr.2017.08.001

DO - 10.1016/j.jcrpr.2017.08.001

M3 - Review article

VL - 4

SP - 123

EP - 126

JO - Journal of Cancer Research and Practice

JF - Journal of Cancer Research and Practice

SN - 2311-3006

IS - 4

ER -